Earnings (Loss) per share

6 Months Ended

Jun. 30, 2026

NOTE 13 – Earnings (Loss) per share:

Basic earnings and loss per share are computed by dividing net income (loss) attributable to Teva’s ordinary shareholders by the weighted average number of ordinary shares outstanding, net of treasury shares.

Basic and diluted earnings (loss) per share attributable to Teva’s ordinary shareholders for the

hree and

six months ended June 30, 2026 and 2025, are calculated as follows:


	Three Months Ended					Six Months Ended
	June 30,					June 30,
	(U.S. $ in millions except share and per share data)
	2026			2025		2026			2025
Basic earnings (loss) attributable to Teva’s ordinary shareholders (numerator):
Net income (loss) attributable to Teva’s ordinary shareholders	$	(576	)	$	282	$	(207	)	$	497

Shares (denominator):
Weighted average shares outstanding		1,165			1,147		1,160			1,142

Basic earnings (loss) attributable to Teva’s ordinary shareholders	$	(0.49	)	$	0.25	$	(0.18	)	$	0.43

Diluted earnings (loss) attributable to Teva’s ordinary shareholders (numerator):
Net income (loss) attributable to Teva’s ordinary shareholders	$	(576	)	$	282	$	(207	)	$	497

Shares (denominator):
Weighted average shares outstanding		1,165			1,147		1,160			1,142
Diluted effect of stock options, RSUs and PSUs		—			14		—			17

Total dilutive shares outstanding		1,165			1,161		1,160			1,159

Diluted earnings (loss) attributable to Teva’s ordinary shareholders	$	(0.49	)	$	0.24	$	(0.18	)	$	0.43

In computing diluted loss per share for the three and six months ended June 30, 2026, no account was taken of the potential dilution that could occur upon the exercise of options and

non-vested

RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. Additionally, an amount of 30.7 million dilutive shares of ordinary shares from the conversion of outstanding stock options, RSUs and PSUs were excluded from the computation of diluted earnings per share attributable to Teva’s ordinary shareholders for the three and six months ended June 30, 2026.

In computing diluted earnings per share for the three and six months ended June 30, 2025, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and

non-vested

RSUs and PSUs granted under employee stock compensation plans. No account was taken of the potential dilution that could occur upon the exercise of convertible senior debentures, since they had an anti-dilutive effect on earnings per share. Additionally, an amount of 31.2 million and 28.8 million dilutive shares of ordinary shares from the conversion of outstanding stock options, RSUs and PSUs were excluded from the computation of diluted earnings per share attributable to Teva’s ordinary shareholders for the three and six months ended June 30, 2025,

respectively